WBI Share Price

Open 0.26 Change Price %
High 0.28 1 Day 0.00 0.00
Low 0.25 1 Week 0.00 0.00
Close 0.28 1 Month 0.00 0.00
Volume 4500 1 Year 0.00 0.00
52 Week High 0.12
52 Week Low 0.08
WBI Important Levels
Resistance 2 0.31
Resistance 1 0.30
Pivot 0.27
Support 1 0.26
Support 2 0.25
CVE Canada Most Active Stocks
PRY 0.02 0.00%
PRY 0.02 0.00%
PRY 0.02 0.00%
PRY 0.02 0.00%
PUM 0.11 37.50%
PUM 0.11 37.50%
GLK 0.06 50.00%
GLK 0.06 50.00%
COD 0.07 0.00%
COD 0.07 0.00%
More..
CVE Canada Top Gainers Stocks
SHL 0.02 100.00%
SHL 0.02 100.00%
SHL 0.02 100.00%
TYE 0.02 100.00%
ELN 0.04 100.00%
ELN 0.04 100.00%
ELN 0.04 100.00%
ELN 0.04 100.00%
BXR 0.02 100.00%
CAP 0.02 100.00%
More..
CVE Canada Top Losers Stocks
KLM 0.01 -50.00%
FEM 0.02 -50.00%
FEM 0.02 -50.00%
FEM 0.02 -50.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
GNT 0.13 -35.00%
More..

Welichem Biotech Inc (CVE: WBI)

WBI Technical Analysis 3
As on 19th Jun 2014 WBI Share Price closed @ 0.28 and we RECOMMEND Sell for LONG-TERM with Stoploss of 0.33 & Sell for SHORT-TERM with Stoploss of 0.31 we also expect STOCK to react on Following IMPORTANT LEVELS.
WBI Target for November
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
WBI Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Medical Laboratories & Research
Offical website http://www.welichem.com
WBI Address
WBI
4475 Weyburne Drive
Suite 316
Burnaby, BC V5G 3L1
Canada
Phone: 604-432-1703
Fax: 604-432-1704
WBI Latest News
Interactive Technical Analysis Chart Welichem Biotech Inc ( WBI CVE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Welichem Biotech Inc
WBI Business Profile
Welichem Biotech Inc., a development stage biotechnology company, engages in the discovery and development of therapeutic drugs for autoimmune diseases and cancers. Its lead drug candidate, WBI-2100, is in the pre-clinical stage of development to treat various cancerous tumors. The company is developing product candidates through its Symbiochem technology platform. Welichem Biotech Inc. is based in Burnaby, Canada.